The 1st AZ hit, the 2nd is a vaccine… Possibility to use’mixed vaccination’ as an incentive for rejectors

Russia “Started clinical trial of’Combined Vaccination with Sputnik V'”
AZ in disbelief, “You can be Pfizer later”, Yuin

A medical worker injects AstraZeneca Corona 19 vaccine into a syringe at a hospital in Halle in eastern Germany. Halle (Germany) = AFP Yonhap News

The’mixed vaccination’, which administers a new coronavirus infection (Corona 19) vaccine that is different from the first vaccination, is emerging as an alternative vaccination method. It is likely to be used as an incentive to attract people who distrust the AstraZeneca (AZ) vaccine and refuse to receive it.

According to Tas News on the 20th (local time), the’Russian Direct Investment Fund’ (RDIF), which is responsible for the development support and overseas production and supply of the Russian-made Corona 19 vaccine’Sputnik V’, posted on Twitter on the day, “2 If you use Sputnik V for primary vaccination, you don’t have to wait three months for the second vaccination,” he said. “A clinical trial of this (combined vaccination) method has already begun.” The combined vaccination test between the two heterogeneous vaccines is conducted with 100 volunteers from three countries, including Azerbaijan, the United Arab Emirates (UAE) and Saudi Arabia. First, the scheduled period is 6 months. This means that as early as this summer, a new plan can be realized.

This combination inoculation scheme is useful for diluting the rejection of certain vaccines. Germany is the country that paid attention to such uses and started actively. German Health Minister Jens Sfan said in a conversation with the citizens who opened the video on the same day, “It is possible without any problem” to get the AZ vaccine first and then receive additional vaccines from other pharmaceutical companies such as Pfizer, Bioentech, and Modena.

What the German government wants to say is that even a vaccine that is relatively ineffective is far better off than not at all. There is a strong perception among Germans that they will receive a Pfizer or Modena vaccine, which is more effective than the AZ vaccine, even if they wait a bit. In fact, the average immunity effect (70.4%) of the AZ vaccine confirmed as a result of the phase 3 clinical trial was weaker than that of Pfizer (95.0%) and Modena (94.1%).

Moreover, the German government has removed those over 65 from the AZ vaccine. This is because the effect targeting the age group is opaque. In such a situation, even the first-line medical workers under the age of 65, who are the top targets for vaccination under the age of 65, have avoided the AZ vaccine. Therefore, 633,000 of the 740,000 doses currently supplied have yet to find the owner.

The solution to this demand imbalance is the idea of ​​mixed inoculation. Even AZ vaccines, which are relatively ineffective in preventing infection, can certainly be prevented from worsening seriously if infected, and “the immunity generated by the AZ vaccine can be further strengthened without any problem with other vaccines” (Karsten Vätzl Germany infectious disease The secretary general of the society) explains the crab experts.

There is no problem, as well as an analysis that there is no possibility that the immune effect of the hybrid method is rather superior. Russia and the UK, which developed the Sputnik V and AZ vaccines, respectively, expect to improve immunity through a single vaccination of each vaccine.

In order to minimize the damage in the presence of mutant viruses, it is best to reach population immunity as quickly as possible through acceleration of vaccination. Israel, which has the world’s highest vaccination rate, issues’green badges’ as a mark to people who have been vaccinated, and attempts to allow some foreign activities, as in combination vaccination, to quickly reduce the number of unvaccinated people.

Kwon Kyung-seong reporter




Subscribe to the Hankook Ilbo News Naver Channel
Subscribe on Newsstand

Balance to see the world, the Hankook Ilbo Copyright © Hankookilbo

Issues you may be interested in

.Source